Actinogen Medical Ltd. has announced the initiation of its XanaMIA phase 2b/3 clinical trial, aimed at assessing the efficacy of Xanamem, a novel oral treatment for Alzheimer's disease. This trial, now open at 20 sites across the United States, is recruiting participants diagnosed with mild to moderate Alzheimer's disease. The study examines the effects of Xanamem, which inhibits the production of cortisol in brain regions associated with memory and critical thinking, compared to a placebo over a 36-week period. Participants who complete this phase will be eligible for an open-label extension trial of Xanamem for up to 24 months, anticipated to commence in early 2026. No results from the trial have been presented yet, as participant recruitment and data collection are ongoing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.